This site is intended only for healthcare professionals resident in India
Menu
Close
Recommended Dosage of Tofacitinib in Patients With PsA1,*
*Tofacitinib is used in combination with DMARDs in patients with PsA. The efficacy of tofacitinib as a monotherapy has not been studied in PsA.
†Use of tofacitinib in patients with severe hepatic impairment is not recommended.
Explore more
ANC, absolute neutrophil count; BID, twice daily; CYP3A4, cytochrome P450 3A4; CYP2C19, cytochrome P450 2C19; DMARD, disease-modifying antirheumatic drug.
Efficacy proven by different studies
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.
PP-UNP-IND-0012 July 2022